Natco Pharma Empowers Patients with Launch of Cost-Effective Everolimus Tablets

Natco Pharma Limited has officially launched its Everolimus tablets, a generic equivalent of AFINITOR DISPERZ, aimed at treating tuberous sclerosis complex (TSC)-related tumors. The launch comes after regulatory approvals in the US, where the drug has seen estimated sales of USD 112 million in the past year. The new product, available in 2mg, 3mg, and 5mg strengths, offers a major breakthrough in affordability, priced at approximately ₹15,900 per bottle—about 97% lower than the imported version from Roche.

This development is a significant step forward in expanding access to life-saving therapies for patients suffering from rare conditions like subependymal giant cell astrocytoma (SEGA). In India, the Delhi High Court recently cleared the way for this affordable generic, marking a victory for public health priorities over patent protections.

The launch strengthens Natco’s reputation as a leader in the complex generics segment, providing a cost-effective alternative while potentially boosting its market share domestically and abroad, particularly as regulatory landscapes continue to evolve towards increasing affordability and access.

Key Highlights

Natco Pharma launches its generic Everolimus tablets for treatment of TSC-related tumors.

Approved by USFDA; available in 2mg, 3mg, and 5mg strengths.

Priced at ₹15,900 per bottle, nearly 97% lower than Roche’s imported drug.

Aims to improve treatment accessibility and affordability globally.

Success follows recent legal victory in India’s patent court, paving the way for significant market penetration.

Estimated industry sales of USD 112 million for the drug in the US last year.

Sources: Economic Times, MoneyControl, CNBC, PharmaNews, Legal & Regulatory Updates